IQ-AI Ltd
(“IQ-AI” or the “Company”)
Imaging Biometrics Software Enhances Clinical Decision-Making at Insel Gruppe AG
May 17, 2024 — Imaging Biometrics (IB), Elm Grove, WI, a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), announces the successful deployment of its state-of-the-art software at Insel Gruppe AG in Bern, Switzerland. This installation was facilitated through Bayer’s Calantic™ platform on which IB’s exclusive algorithms are made available under a partnership agreement.
Clinicians at Insel Gruppe AG are now equipped with IB’s quantitative imaging solutions, renowned for their precision and reliability in aiding critical clinical decisions. The technology is especially beneficial to neuroradiologists, oncologists, and surgeons, providing them with enhanced capabilities to determine the best course of action for their patients swiftly and effectively.
Dr. Arsany Hakim, MD, Head of Brain Tumor Imaging at the Institute of Diagnostic and Interventional Neuroradiology, stated, “The incorporation of IB’s software into our clinical workflow marks a significant step towards the standardization of advanced imaging, enhancing both clinical workflow and patient care. We are eager to utilize the capabilities offered by IB’s solutions in our team to enhance lesion detection and to advance patient monitoring process, ultimately to improve patient outcomes”.
Echoing this sentiment, Prof. Roland Wiest, MD, Deputy Director of Neuroradiology at Insel Gruppe AG, commented, “The adoption of IB’s advanced imaging is expected to be a game-changer in our patient care strategy. We foresee an immediate enhancement in our ability to tailor treatments to individual needs.”
“We are thrilled to witness the integration of our Calantic partner, Imaging Biometrics, into the everyday clinical workflow at Insel Gruppe AG, where it stands poised to provide invaluable support to radiologists and their teams,” said Lucia Fernandez Lopez, Head of Digital Solutions Business EMEA, Radiology at Bayer. “With its precise imaging tools, the platform empowers enhanced diagnostics and treatment planning, fostering efficiency in image analysis while offering advanced capabilities for biomarker quantification. These advantages collectively elevate clinical decision-making, ultimately optimizing patient care within the radiology practice.”
Michael Schmainda, CEO of Imaging Biometrics, reflected on the significance of this collaboration: “The installation at Insel Gruppe AG allows them full access to our comprehensive suite of applications. We are excited about this collaboration and are committed to supporting Insel Gruppe AG as they set new standards in patient care.”
–ENDS–
The Directors of the Company accept responsibility for the contents of this announcement.
For further information, please contact:
IQ-AI Ltd
Trevor Brown/Vinod Kaushal/Brett Skelly/Michael Schmainda
Tel: 020 7469 0930
Peterhouse Capital Limited (Financial Adviser and Broker)
Lucy Williams/Heena Karani
Tel: 020 7220 9797
About Insel Gruppe AG
Insel Gruppe AG, one of the longest-running university hospitals in Europe, was founded in 1354 and has since become a leading medical institution in Europe, playing a pivotal role in medical education and training. Housing 8 MRI scanners and conducting over 23,000 MRI scans annually, the University Institute of Diagnostic and Interventional Neuroradiology at Insel Gruppe AG stands as the largest neuroradiology department in Switzerland. The department is equipped with state-of-the-art technology, including high-field MRI, and is nationally and internationally recognized for its clinical excellence and contributions to the field. In collaboration with the departments of Neurosurgery, Clinical Oncology, Radiation Therapy, Pathology, and Neurology, the Brain Tumor Center in Bern is renowned across Switzerland. It offers advanced diagnostic services and personalized patient management.
About Imaging Biometrics® LLC
IB is a wholly owned subsidiary of IQ-AI Limited, (LON: IQAI), and focuses on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively. For more information about Imaging Biometrics, visit the company’s website at www.imagingbiometrics.com. Follow IB on X, @IQAI_IB.
About Calantic Digital Solutions by Bayer
Calantic Digital Solutions is a suite of digital radiology AI-enabled applications that assist radiologists and their teams at critical steps within a patient’s treatment journey. The vendor-neutral, cloud-hosted platform includes a growing number of applications designed to aid in prioritization, lesion detection and quantification, as well as apps that automate routine tasks and measurements, improve radiology suites’ workflow, and free up time for radiologists and their teams. The offering is orchestrated by body region and will include tools designed to help with thoracic, neurological, breast, prostate, cardiac and liver imaging.